Clinical trial
Open access
Aug 2026
Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial
The CV0701 and CV0601 mRNA vaccines elicited robust humoral and cellular immunity with an acceptable safety profile, comparable to a licensed, bivalent mRNA vaccine.
Robynne Wong, A. Kuznetsova, Emna Baba et al.
· Human Vaccines & Immunothera... · 0 citations